Welcome to our dedicated page for Sherwin-Williams SEC filings (Ticker: SHW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sharp swings in titanium dioxide prices, environmental obligations that span decades, and a 5,000-store retail footprint make Sherwin-Williams SEC filings anything but routine. If you have ever searched hundreds of pages to locate raw-material cost disclosures or wondered whether a newly acquired coatings brand will lift margins, this page is for you.
Stock Titan’s AI distills every Sherwin-Williams document—from the annual report (10-K) to real-time Form 4 insider transactions—into concise, plain-English takeaways. Need to spot a pigment price warning buried in a “Risk Factors” section? Our engine flags it. Looking for store-count changes across the Paint Stores, Consumer Brands, and Performance Coatings groups? We surface those numbers instantly. You can even ask natural questions like “understanding Sherwin-Williams SEC documents with AI” and receive context-rich answers.
Here’s what you’ll find below:
- Sherwin-Williams quarterly earnings report 10-Q filing summaries that highlight segment margins and commodity trends.
- Sherwin-Williams 8-K material events explained so you grasp mergers, plant closures, or supply-chain updates the moment they post.
- Sherwin-Williams proxy statement executive compensation tables broken down for quick peer comparison.
- Sherwin-Williams Form 4 insider transactions real-time alerts to track executive stock moves ahead of earnings.
Whether you are monitoring paint demand cycles, assessing environmental reserves, or checking a Sherwin-Williams annual report 10-K simplified for long-term cash-flow drivers, our platform turns dense filings into actionable insight—so you spend minutes, not hours, getting the full color on SHW.
Banco de Chile (NYSE: BCH) has disclosed via a Form 6-K that it completed an offshore bond placement under its Medium-Term Note (MTN) program. On 9 July 2025 the bank issued MXN 1,000,000,000 (≈US$55 million) in notes maturing 17 July 2030. The bonds were priced at TIIE-28d + 105 bps, signalling demand for BCH credit at a modest spread over the Mexican interbank benchmark. The proceeds, tenor and any specific use of funds were not detailed in the filing.
The transaction extends the bank’s debt maturity profile by five years and adds peso-denominated funding from international investors, supporting balance-sheet diversification. No further financial metrics, covenants, or comparative cost of funding were provided.
Biotechnology Value Fund and affiliated entities have filed a Schedule 13G disclosing a collective 7.4% passive stake in Nektar Therapeutics (NASDAQ: NKTR). The filing, dated 9 July 2025 with an event date of 1 July 2025, reports aggregate beneficial ownership of 1,276,595 common shares out of 17,301,061 shares outstanding following the company’s recent public offering.
The ownership is spread across multiple Delaware and Cayman-based vehicles: Biotechnology Value Fund (LP) holds 661,758 shares (3.8%), Biotechnology Value Fund II (LP) holds 517,813 shares (3.0%), and Biotechnology Value Trading Fund OS (LP) holds 71,367 shares (<1%). Control is exercised jointly through the general partners BVF GP Holdings LLC and BVF Partners L.P., with Mark N. Lampert signing on behalf of each entity. All shares are held with shared voting and dispositive power; none of the reporting persons claims sole authority.
The filing is made on Form 13G—indicating a passive investment intent rather than an activist position— and includes the customary certification that the securities were not acquired to influence control of the issuer. No other material transactions, derivatives, or lock-up arrangements are disclosed.
Key take-aways for investors: BVF’s aggregated 7.4% stake makes it one of the largest outside shareholders of Nektar, signalling confidence from a specialist biotech investor group. However, because the filing is passive, immediate governance or strategic changes should not be expected.
Sherwin-Williams (SHW) Form 4 filing overview
Sherwin-Williams director Kerrii B. Anderson reported a small, routine acquisition of deferred stock units on 7 July 2025 under the company’s 2005 Director Deferred Fee Plan. The filing shows:
- Transaction: 28.86 deferred stock units (economic equivalent of one common share each) were credited to Anderson’s account at a weighted-average reference price of $346.53.
- Nature: Exempt, automatic deferral of director fees rather than an open-market share purchase; units become payable in common stock after Anderson leaves the board.
- Post-transaction beneficial ownership: 948.59 deferred stock units held indirectly through the plan, plus 5,261 directly held equity interests (4,111 common shares and 1,150 restricted stock units).
- Ownership status: Anderson remains a non-executive director and files individually.
The activity is de minimis relative to Sherwin-Williams’ 255 million share count and does not signal a directional view on the stock. It is primarily an administrative conversion of board fees into equity and therefore carries limited investment significance.
FAQ
What is the current stock price of Sherwin-Williams (SHW)?
What is the market cap of Sherwin-Williams (SHW)?
What is the primary business of Sherwin-Williams?
Which segments does Sherwin-Williams operate in?
How does Sherwin-Williams maintain its market presence?
What distinguishes Sherwin-Williams in the competitive paints and coatings industry?
How does the company support its diverse customer base?
What role does innovation play in Sherwin-Williams' operations?
How does Sherwin-Williams approach quality assurance?
In what markets does Sherwin-Williams operate globally?
